Compass Therapeutics (CMPX) vs Innate Pharma S.A. (IPHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Innate Pharma S.A. (IPHA) has outperformed Compass Therapeutics (CMPX) over the past year, losing 22.1% versus a loss of 71.7%. Over five years, CMPX leads with a -68.2% price change compared with -74.1% for IPHA. Compass Therapeutics is the larger company by market cap ($183.7 million vs $169.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | IPHA |
|---|---|---|
| Share price | $1.02 | $1.52 |
| Market cap | $183.69M | $169.78M |
| 1-day change | +2.19% | -4.40% |
| YTD return | -81.01% | -13.14% |
| 1-year return | -71.75% | -22.05% |
| 5-year return | -68.22% | -74.11% |
| EPS (TTM) | $-0.39 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $2.71 |
| 52-week low | $0.829 | $1.17 |
| Distance from 52-week high | -85.17% | -43.91% |
| Analyst consensus | buy | none |
| Avg. price target upside | +434.31% | +338.82% |
| Average volume | 4.08M | 158.98K |
| Shares outstanding | 180.09M | 111.70M |
| Employees | 39 | 120 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPHA has outperformed CMPX by 49.7 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Healthcare · Biotechnology · 39 employees
About Innate Pharma S.A.
IPHA stock →Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
Healthcare · Biotechnology · 120 employees
CMPX vs IPHA FAQ
Which is bigger, Compass Therapeutics or Innate Pharma S.A.?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $183.69M compared with $169.78M for Innate Pharma S.A. (IPHA).
Which stock has performed better over the past year, CMPX or IPHA?
IPHA returned -22.05% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Innate Pharma S.A. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.